TOP TEN perturbations for 1552783_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552783_at
Selected probe(set): 1552783_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552783_at (1552783_at) across 6672 perturbations tested by GENEVESTIGATOR:

dengue fever study 10 (DF) / normal naive CD8 T cell sample

Relative Expression (log2-ratio):-0.98882294
Number of Samples:3 / 5
Experimental dengue fever study 10 (DF)
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.
Control normal naive CD8 T cell sample
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.

Sjogren's syndrome study 11 (CD4 TN) / normal peripheral blood CD4 naive T-cell sample

Relative Expression (log2-ratio):0.97481155
Number of Samples:6 / 6
Experimental Sjogren's syndrome study 11 (CD4 TN)
Naive CD4 T-cells (TN) isolated from peripheral blood of patients with primary Sjogren's syndrome (pSS). Patient characteristics: 64.67 ± 15.93y; ESSDAI 0.17 ± 0.41; 3 patients RF positive; 3 patients RO_SSA positive; 1 patient LA_SSB positive; 6 patients ANA positive. Exclusion criteria: patients who were being treated with moderate to high doses of corticosteroids, immunosuppressants or biological agents. FACS markers: CD3+CD4+CD45RA+CCR7+
Control normal peripheral blood CD4 naive T-cell sample
Peripheral blood CD4 naive T-cell samples (TN) derived from healthy control subjects who did not have autoimmune diseases or were not receiving any drugs. Donor characteristics: age 43.33±5.72 year; 6 females. FACS markers: CD3+CD4+CD45RA+CCR7+

psoriasis study 5 (NCT00867100; non-lesional; baseline) / psoriasis study 5 (Asterand; non-lesional; baseline)

Relative Expression (log2-ratio):0.9675493
Number of Samples:24 / 14
Experimental psoriasis study 5 (NCT00867100; non-lesional; baseline)
Non-lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from uninvolved, non-lesional skin at baseline.
Control psoriasis study 5 (Asterand; non-lesional; baseline)
Non-lesional skin punch biopsies derived from patients (23-71 years old) with mild to moderate psoriasis (Asterand data set; Set 1). Patients did not use any medication for psoriasis. A 5mm punch biopsy was obtained from uninvolved, non-lesional skin.

obesity study 5 (sensitive) / normal blood sample

Relative Expression (log2-ratio):0.9619436
Number of Samples:9 / 20
Experimental obesity study 5 (sensitive)
Fasting whole blood samples derived from obese, diet-sensitive patients during caloric restriction (week 6 after entry into Ottawa Hospital Weight Management Program). Patients had a BMI 30-50 kg/m2 and were excluded if having medical conditions that might affect blood gene expression (e.g. TSH or free T3 levels out of range at week 1 or week 13, insulin or oral hypoblycemic drug treated diabetes mellitus, cigarette smoking, congestive heart failure, obstructive sleep apnea, or active malignancy). Patients were also excluded if treated with weight-altering medications (e.g. tricyclic antidepressants, paroxetine, mirtazepine, lithium, valproate, gabapentin, typical and atypical antipsychotics, fluoxetine (>20mg), bupropion, topiramate, systemic glucocorticoids, or any weight management drugs).
Control normal blood sample
Fasting whole blood samples derived from lean control patients. Patients had a BMI ≤ the 10th percentile (age and sex) and haven´t had a BMI> 25th percentile for more than a 2 year consecutive period. Patients were excluded if having any medical conditions that affect weight gain (e.g. hyperthyroidism, anorexia nervosa, bulimia, major depression, or malabsorption syndrome).

Burkitt lymphoma study 2 (immunodeficiency-associated) / Burkitt lymphoma study 1 (endemic)

Relative Expression (log2-ratio):0.94044495
Number of Samples:2 / 13
Experimental Burkitt lymphoma study 2 (immunodeficiency-associated)
Tumor tissue samples from the lymph node of children with immunodeficiency-associated Burkitt lymphoma (ID-BL).
Control Burkitt lymphoma study 1 (endemic)
Tumor tissue samples from the lymph node of children with endemic Burkitt lymphoma (eBL).

systemic onset JIA study 6 (baseline; placebo) / normal blood sample

Relative Expression (log2-ratio):0.8541398
Number of Samples:22 / 22
Experimental systemic onset JIA study 6 (baseline; placebo)
Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted.
Control normal blood sample
Whole blood samples collected from healthy volunteers.

glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):0.8261852
Number of Samples:3 / 3
Experimental glioma study 17 (astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

dendritic cell study 6 (CpG A) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-0.8047271
Number of Samples:7 / 8
Experimental dendritic cell study 6 (CpG A)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Langerhans cell histiocytosis study 3 / normal tonsillar T-lymphocyte sample

Relative Expression (log2-ratio):-0.6596384
Number of Samples:10 / 4
Experimental Langerhans cell histiocytosis study 3
CD3+ T-lymphocyte samples isolated from Langerhans cell histiocytosis (LCH) lesions in bone (8 cases) or skin (2 cases). Patient with different clinical status were included in this study (unifocal, single system; multifocal, single system and multifocal, multisystem disease).
Control normal tonsillar T-lymphocyte sample
Normal tonsillar CD3+ T-lymphocytes were isolated from children who undergone elective tonsillectomy. The T-cells were isolated from presumably healthy tissue.

precursor-B-ALL study 3 (hyperdiploid) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):-0.515337
Number of Samples:17 / 5
Experimental precursor-B-ALL study 3 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).